Department of Immunology, Genetics and Pathology, Uppsala University, Science for Life Laboratory, Uppsala, 75108, Sweden; School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia; All authors contributed equally to this work; ORCID: 0000-0001-6085-6749 (A. Ameur) and 0000-0003-3357-4580 (W.P. Kloosterman).
Department of Genetics, Center for Molecular Medicine, UMC Utrecht, Utrecht, 3584 CG, The Netherlands; All authors contributed equally to this work; ORCID: 0000-0001-6085-6749 (A. Ameur) and 0000-0003-3357-4580 (W.P. Kloosterman).
Trends Biotechnol. 2019 Jan;37(1):72-85. doi: 10.1016/j.tibtech.2018.07.013. Epub 2018 Aug 13.
In the past several years, single-molecule sequencing platforms, such as those by Pacific Biosciences and Oxford Nanopore Technologies, have become available to researchers and are currently being tested for clinical applications. They offer exceptionally long reads that permit direct sequencing through regions of the genome inaccessible or difficult to analyze by short-read platforms. This includes disease-causing long repetitive elements, extreme GC content regions, and complex gene loci. Similarly, these platforms enable structural variation characterization at previously unparalleled resolution and direct detection of epigenetic marks in native DNA. Here, we review how these technologies are opening up new clinical avenues that are being applied to pathogenic microorganisms and viruses, constitutional disorders, pharmacogenomics, cancer, and more.
在过去的几年中,单分子测序平台,如 Pacific Biosciences 和 Oxford Nanopore Technologies 的平台,已经可供研究人员使用,并正在测试其在临床应用中的适用性。这些平台提供了非常长的读取序列,使得可以直接对短读长平台无法访问或难以分析的基因组区域进行测序。这包括致病的长重复元件、极端 GC 含量区域和复杂的基因座。同样,这些平台还能够以前所未有的分辨率对结构变异进行特征描述,并直接检测天然 DNA 中的表观遗传标记。在这里,我们将回顾这些技术如何为致病性微生物和病毒、先天疾病、药物基因组学、癌症等领域开辟新的临床途径。